137 related articles for article (PubMed ID: 844999)
1. Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors.
Lamm DL; Harris SC; Gittes RF
Invest Urol; 1977 Mar; 14(5):369-72. PubMed ID: 844999
[TBL] [Abstract][Full Text] [Related]
2. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
3. Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.
Adolphs HD; Thiele J; Kiel H
Urol Res; 1979 Jun; 7(2):71-8. PubMed ID: 473445
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.
Ibraheim EH; El Kappany H; Nigam VN; Brailovsky CA; Madarnas P; Elhilali MM
Anticancer Res; 1984; 4(3):209-13. PubMed ID: 6465859
[TBL] [Abstract][Full Text] [Related]
5. Intralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
Hess AD; Catchatourian R; Zander AR; Epstein RB
Cancer Res; 1977 Nov; 37(11):3990-4. PubMed ID: 143344
[TBL] [Abstract][Full Text] [Related]
6. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
7. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
[TBL] [Abstract][Full Text] [Related]
9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
10. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
Lee YT
Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the intravesical MTP and BCG treatment of transplantable bladder cancer.
Elhilali MM; Ibrahim EH; Nigam VN; Brailovsky CA; Madarnas P
J Urol; 1983 Jun; 129(6):1265-9. PubMed ID: 6854814
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of bladder cancer with intralesional injection with BCG.
Calsini P; Scapicchi G; Gazzarini O; Melone F; Aulisi A; Pellegrini G; Fabris N; Provinciali M
J Exp Pathol; 1987; 3(4):579-86. PubMed ID: 3454805
[TBL] [Abstract][Full Text] [Related]
14. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
16. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
Soloway MS
Natl Cancer Inst Monogr; 1978 Dec; (49):327-32. PubMed ID: 748788
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
Debruyne FM; Witjes JA; vd Meijden AP
Arch Esp Urol; 1990; 43 Suppl 2():133-8. PubMed ID: 2096774
[No Abstract] [Full Text] [Related]
20. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
